Shares of Sarepta Therapeutics (NASDAQ: SRPT) dropped briefly on Wednesday, giving back all their gains on the session, after a tweet from a twitter account called @citronresearc.
The tweet states: "$SRPT FDA steps in as its 48 weeks results on Eteplirsen results are tainted and have been doctored they believe Trial papers seized by FDA."
Given the twitter handle and picture of a yellow lemon, the account appears to be an impostor of @citronresearch, the twitter handle of Citron Research run by Andrew Left.
Citron Research is a short seller that has targeted companies like Intuitive Surgical (NASDAQ: ISRG), Questcor (NASDAQ: QCOR) and Usana (NYSE: USNA).
The tweet from @citronresearc comes just one day after someone pretending to be Muddy Waters made statements critical of Audience (NASDAQ: ADNC).
Posted-In: News Short Sellers Rumors Intraday Update Movers
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.